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Abstract
▼
This	study	was	designed	to	assess	the	beneficial	
effects	 of	 high-dose	 (cholecalciferol)	 vitamin	 D	
supplementation	on	metabolic	profiles	and	preg-
nancy outcomes among pregnant women at risk 
for pre-eclampsia. This randomized double-blind 
placebo-controlled clinical trial was performed 
among 60 pregnant women at risk for pre-eclamp-
sia according to abnormal uterine artery Doppler 
waveform. Subjects were randomly divided into 2 
groups to receive 50 000 IU vitamin D supple-
ments	(n	=	30)	or	receive	placebo	(n	=	30)	every	2	
weeks	 from	20	to	32	weeks	of	gestation.	Fasting	
blood samples were taken at baseline study and 
12 weeks after the intervention to quantify rele-
vant variables. Newborn’s anthropometric meas-
urements were determined. Pregnant women 
who received cholecalciferol supplements had 
significantly	increased	serum	25-hydroxyvitamin	
D	concentrations	(	+	17.92	±	2.28	vs.		+	0.27	±	3.19	ng/
ml,	 p	<	0.001)	 compared	 with	 the	 placebo.	 The	
administration of cholecalciferol supplements, 
compared	with	 the	 placebo,	 resulted	 in	 signifi-
cant	differences	in	serum	insulin	concentrations	
(	+	1.08	±	6.80	vs.	 	+	9.57	±	10.32	μIU/ml,	p	<	0.001),	
homeostasis model of assessment-insulin resist-
ance	 (HOMA-IR)	 (	+	0.19	±	1.47	 vs.	 	+	2.10	±	2.67,	
p	<	0.001),	 homeostatic	 model	 assessment-beta	
cell	function	(HOMA-B)	(	+	5.82	±	29.58	vs.		+	39.81 
	±	38.00,	p	<	0.001)	and	quantitative	insulin	sensi-
tivity	check	index	(QUICKI)	score	(	−	0.009	±	0.03	
vs.		−	0.04	±	0.03,	p	=	0.004).	Furthermore,	cholecal-
ciferol-supplemented pregnant women had inc-
reased	 HDL-cholesterol	 concentrations	 (	+	2.67	 
±	8.83	vs.		−	3.23	±	7.76	mg/dl,	p	=	0.008)	compared	
with the placebo. Finally, cholecalciferol supple-
mentation	led	to	a	significant	rise	in	plasma	total	
antioxidant	 capacity	 (TAC)	 concentrations	
(	+	79.00	±	136.69	 vs.	 	−	66.91	±	176.02	mmol/l,	
p	=	0.001)	compared	with	the	placebo.	Totally,	the	
administration of cholecalciferol supplements 
among pregnant women at risk for pre-eclampsia 
for	 12	 weeks	 had	 favorable	 effects	 on	 insulin	
metabolism parameters, serum HDL-cholesterol, 
and plasma TAC concentrations.
Supporting Information for this article is available 
online	at	http://www.thieme-connect.de/products.
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Introduction
▼
Pre-eclampsia is a disorder characterized by pregnancy-induced 
hypertension and new-onset proteinuria occurring after 20 
weeks of gestation in a previously normotensive women [1]. The 
prevalence	of	pre-eclampsia	has	reported	between	1.3–6.7	%	of	
all pregnancies [2]. Despite numerous attempts at early diagno-
sis and treatment, to date, no method has been found that pre-
vents	 the	 development	 of	 pre-eclampsia	 [3].	 Increased	
biomarkers of oxidative stress are considered to be a key factor 
in	 pre-eclampsia	 process	 [4].	 In	 addition,	 decreased	maternal	
plasma	ascorbic	acid	concentrations	[4],	increased	synthesis	of	
free	radicals	and	reactive	oxygen	species	(ROS)	in	the	placenta	
[5], and reduced activities of antioxidant enzymes [6] may lead 
to the development of pre-eclampsia.
Various therapeutic strategies for prevention of pre-eclampsia 
are	proposed	including	the	use	of	aspirin	[7],	antioxidant	sup-
plementation,	especially	vitamins	C	and	E	[8],	and	the	use	of	low	
molecular	weight	 heparin	 [9].	 Previous	 studies	 have	 reported	
that intake of cholecalciferol supplements can rise glutathione 
levels and reduce the production of lipid peroxidation products 
[10, 11], which in turn, would result in decreased oxidative 
stress. These observations result in the hypothesis that early 
supplementation with high-dose cholecalciferol could be useful 
in decreased biomarkers of oxidative stress as well as improving 
vascular endothelial function, thereby preventing or ameliorat-
ing the course of pre-eclampsia. Taking 100 000 IU vitamin D 
supplements	 among	patients	with	gestational	diabetes	 (GDM)	
showed improved insulin function, decreased total- and LDL-
cholesterol concentrations after 6 weeks [12]. In addition, in a 
meta-analysis study it has been shown that pregnant women 
who received vitamin D supplements in early pregnancy had 
lower	odds	of	pre-eclampsia	[13].	Vitamin	D	supplementation	in	
healthy	nulliparous	women	did	affect	pregnancy	outcome	with	
regard	to	pre-eclampsia	[14].
The	favorable	effects	of	cholecalciferol	supplementation	on	met-
abolic	 profiles	 and	 pregnancy	 outcomes	might	 result	 from	 its	
effect	on	apolipoprotein	gene	expression	[15],	parathyroid	hor-
mone	(PTH)	suppression	[16],	improved	insulin	sensitivity	[17],	
and decreased production of lipid peroxidation products [11]. 
We	are	aware	that	no	study	had	examined	the	beneficial	effects	
of high-dose cholecalciferol supplementation on metabolic pro-
files,	 biomarkers	 of	 inflammation,	 oxidative	 stress,	 and	 preg-
nancy outcomes in pregnant women at risk for pre-eclampsia. 
The current study was, therefore, performed to investigate the 
favorable	effects	of	cholecalciferol	administration	on	metabolic	
status and pregnancy outcomes in pregnant women at risk for 
pre-eclampsia.
Subjects and Methods
▼
Participants
Between	July	2014	and	October	2014,	we	did	a	randomized	dou-
ble-blind placebo-controlled clinical trial in Arak, Iran. For esti-
mating sample size, we used a randomized clinical study sample 
size	formula	where	type	1	(α)	and	type	2	errors	(β)	were	0.05	
and	 0.20	 (power	=	80	%),	 respectively.	 According	 to	 a	 previous	
study	[18],	we	also	considered	0.9	as	SD	and	0.55	cm	as	the	dif-
ference	in	the	mean	(d)	of	newborns’	length	at	birth	as	the	key	
variable. Based on this, we needed 25 pregnant women in each 
group	to	have	80	%	power	of	the	study.	However,	we	recruited	30	
subjects	 in	each	group	(totally,	60	patients)	 to	compensate	 for	
the probable loss to follow-up. In the present study, our inclu-
sion	 criteria	were	 pregnant	women	 primigravida,	 aged	 18–40	
years	old	and	at	risk	for	pre-eclampsia.	Women	were	identified	
as	“at-risk”	by	abnormal	uterine	artery	Doppler	waveform	(18–
20	weeks’	gestation,	mean	resistance	index	>	0.67	or	pulsatility	
index > 1.65 with or without the presence of unilateral or bilat-
eral	diastolic	notches)	[19].	We	excluded	pregnant	women	who	
were unable or unwilling to give written informed consent, hav-
ing abnormal fetal anomaly scan, or were being treated with 
warfarin. Gestational age was assessed from the date of last 
menstrual period and concurrent clinical assessment [20]. The 
present trial protocol was approved by the Ethics Committee of 
Arak	 University	 of	 Medical	 Sciences	 (AUMS)	 (Registration	 no.	
92-12-161).	All	pregnant	women	signed	 the	written	 informed	
consent to take part in the current study. This study was regis-
tered	 in	 the	 Iranian	 website	 (www.irct.ir)	 for	 registration	 of	
clinical	trials	(IRCT	code:	IRCT201410035623N27).
Study design
After	 stratification	 for	 pre-intervention	BMI	 (<	25	 and	 	≥	25	kg/
m2)	 and	maternal	 age	 (<	30	 and	 	≥	30	 years),	 pregnant	women	
were randomly allocated into 2 groups to take either cholecalcif-
erol	supplements	(n	=	30)	or	placebo	(n	=	30).	A	trained	midwife	
at maternity clinic did the randomized allocation sequence with 
a computer random number generator. An investigator with no 
clinical involvement in our study packed cholecalciferol and pla-
cebos in numbered bottles based on the random list. Randomi-
zation and allocation were hidden from the researchers and 
pregnant women until the statistical analysis was completed. 
Pregnant women either received one oral pearl containing of 
50	000	IU	vitamin	D3	(D-Vitin	50	000;	Zahravi	Pharm	Co,	Tabriz,	
Iran)	or	a	placebo	(Barij	Essence	Co,	Kashan,	Iran)	every	14	days	
for	12	weeks	 from	20	to	32	weeks	of	gestation.	Placebo	pearls	
were	similar	in	color,	shape,	size,	and	package	to	the	vitamin	D3	
ones	and	contained	edible	paraffin.	Subjects	were	requested	not	
to alter their regular physical activity or normal dietary intakes 
throughout the study and not to take any supplements other 
than the one provided to them by the investigators. All pregnant 
women	were	 also	 taking	 400	μg/d	 folic	 acid	 from	 the	 start	 of	
pregnancy,	 60	mg/d	 ferrous	 sulfate	 from	 the	 second	 trimester,	
and	a	multivitamin	mineral	capsule	(containing	400	IU	vitamin	
D)	from	the	second	half	of	pregnancy.	Both	dietary	and	physical	
activity	records	were	taken	at	week	3,	6,	and	9	of	intervention.	
The dietary records were based on estimated values in household 
measurements. To obtain nutrient intakes of participants accord-
ing	to	these	3-day	food	diaries,	we	used	Nutritionist	IV	software	
(First	Databank,	San	Bruno,	CA,	USA)	modified	for	Iranian	foods.
Assessment of anthropometric variables
Information on pre-pregnancy weight and BMI were obtained 
from the records of pregnant women existed in the clinic. A 
trained midwife at maternity clinic did anthropometric meas-
urements at the beginning of the study and the end of the inter-
vention. Height was measured without shoes using stadiometer 
with a precision of 0.1 cm. Weight was measured in light cloth-
ing	 to	 the	 nearest	 0.1	kg.	 BMI	was	 determined	 as	weight	 (kg)	
divided	by	squared	height	(m2).
Primary and secondary outcomes
Primary outcomes were pre-eclampsia rate, low birth weight 
(LBW)	 (<	2	500	g),	 newborn’s	 birth	 size,	 and	 preterm	 delivery	
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(<	37	weeks).	 Secondary	 outcomes	were	metabolic	 concentra-
tions,	biomarkers	of	inflammatory	factors,	oxidative	stress,	and	
blood pressures.
Biochemical analysis
Fasting	 blood	 samples	 (10	ml)	 were	 taken	 at	 baseline	 and	 12	
weeks after the intervention at Arak reference laboratory at 
early morning after an overnight fast. Blood samples were 
immediately	centrifuged	(Hettich	78532,	Tuttlingen,	Germany)	
at	 3	500	rpm	 for	 10	min	 to	 separate	 serum.	 Then,	 the	 samples	
were	 stored	 at	 	−	70	°C	 before	 analysis	 at	 the	 AUMS	 reference	
laboratory. Serum 25-hydroxyvitamin D concentrations was 
assayed	by	a	commercial	ELISA	kit	(IDS,	Boldon,	UK).	The	inter-	
and intra-assay CVs for serum 25-hydroxyvitamin D assays 
ranged	from	4.9	to	7.2	%.	Commercial	kits	were	used	to	measure	
fasting	plasma	glucose	 (FPG),	 triglycerides,	 cholesterol,	VLDL-,	
LDL-	and	HDL-cholesterol	concentrations	(Pars	Azmun,	Tehran,	
Iran).	The	intra-	and	inter-assay	CVs	for	FPG	and	lipid	concentra-
tions	 were	 	<	5	%.	 Serum	 insulin	 was	 assayed	 by	 ELISA	 kit	
(Monobind,	CA,	USA).	The	intra-	and	inter-assay	CVs	for	serum	
insulin	were	2.9	and	5.9	%,	 respectively.	Homeostasis	model	of	
assessment-insulin	 resistance	 (HOMA-IR)	 and	 β-cell	 function	
(HOMA-B)	 and	 quantitative	 insulin	 sensitivity	 check	 index	
(QUICKI)	 was	 calculated	 based	 on	 suggested	 formulas	 [21].	
Serum	high	sensitivity	C-reactive	protein	(hs-CRP)	was	quanti-
fied	using	ELISA	kit	(LDN,	Nordhorn,	Germany)	with	intra-	and	
inter-assay	 CVs	 of	 2.4	 and	 3.9	%,	 respectively.	 Plasma	 nitrite/
nitrate	(NOx),	taken	as	an	index	of	nitric	oxide	(NO)	concentra-
tion,	was	determined	using	the	Giess	method	modified	by	Tatsh	
et	al.	[28].	Plasma	total	antioxidant	capacity	(TAC)	was	assessed	
by	the	use	of	ferric	reducing	antioxidant	power	(FRAP)	method	
developed by Benzie and Strain [22]. The plasma total glu-
tathione	(GSH)	and	malondialdehyde	(MDA)	were	measured	by	
the	method	of	Beutler	et	al.	[23]	and	thiobarbituric	acid	reactive	
substance	(TBARs)	spectrophotometric	test	[24].
Statistical analysis
Distribution of data related to normality was assessed by Kol-
mogorov-Smirnov test. Independent sample Student’s t-test was 
used to detect changes in general characteristics and dietary 
intakes	 between	 the	 2	 groups.	 Comparisons	 of	 changes	 (end-
point	minus	baseline)	12	weeks	after	the	intervention	between	
the 2 groups were done by two-way repeated measures analysis 
of	 variance.	 In	 this	 analysis,	 the	 treatment	 (cholecalciferol	 vs.	
placebo)	was	regarded	as	between-subject	factor	and	time	with	
2	 time-points	 (baseline	 and	 12	 weeks	 after	 the	 intervention)	
was considered as within-subject factor. To control for con-
founding	 variables,	 analysis	 of	 covariance	 (ANCOVA)	 test	 was	
used	to	determine	the	differences	between	the	2	groups	post-
intervention, while adjusting for baseline measurements, mater-
nal age and baseline BMI. A p-value of  < 0.05 was considered as 
statistically	significant.	All	statistical	analyses	were	done	using	
the	Statistical	Package	 for	Social	Science	version	17	 (SPSS	 Inc.,	
Chicago,	IL,	USA).
Results
▼
Totally,	60	pregnant	[cholecalciferol	(n	=	30)	and	placebo	(n	=	30)]	
completed the trial. On average, the rate of compliance in our 
study	was	high,	such	that	100	%	of	pearls	were	taken	throughout	
the trial in both groups. Compliance with the consumption of 
vitamin D supplements and placebos was monitored every 2 
weeks	 through	 telephone	 interviews	 and	 by	 the	 use	 of	 3-day	
dietary	records	completed	at	week	3,	6,	and	9	of	intervention.
Mean age, pre-pregnancy weight and BMI of pregnant women 
was	27.4	±	5.2	years,	64.5	±	10.6	kg	and	25.9	±	4.6	kg/m2, respec-
tively. Baseline and end-of-trial means of weight and BMI were 
not	significantly	different	between	cholecalciferol	and	placebo	
groups	(Data	not	shown).
Based on the three-day dietary records obtained throughout the 
intervention,	no	significant	change	was	seen	between	the	two	
groups in terms of dietary intakes of energy, carbohydrates, pro-
teins,	 fats,	 saturated	 fatty	 acids	 (SFA),	 polyunsaturated	 fatty	
acids	(PUFA),	monounsaturated	fatty	acids	(MUFA),	cholesterol,	
dietary	fiber,	vitamin	D,	calcium,	phosphors,	magnesium,	zinc,	
manganese,	selenium,	and	vitamin	C	(Data	not	shown).
Pregnant women who received cholecalciferol supplements had 
significantly	increased	serum	25-hydroxyvitamin	D	concentra-
tions	(	+	17.92	±	2.28	vs.	 	+	0.27	±	3.19	ng/ml,	p	<	0.001)	compared	
with	the	placebo	(	●▶	 Table 1).	The	administration	of	cholecalcif-
erol supplements, compared with the placebo, resulted in 
	significant	 differences	 in	 serum	 insulin	 concentrations	
(	+	1.08	±	6.80	 vs.	 	+	9.57	±	10.32	μIU/ml,	 p	<	0.001),	 HOMA-IR	
(	+	0.19	±	1.47	vs.		+	2.10	±	2.67,	p	<	0.001),	HOMA-B	(	+	5.82	±	29.58	
vs.	 	+	39.81	±	38.00,	 p	<	0.001)	 and	 QUICKI	 score	 (	−	0.009	±	0.03	
vs.		−	0.04	±	0.03,	p	=	0.004).	Furthermore,	cholecalciferol-supple-
mented pregnant women had increased HDL-cholesterol 
	concentrations	 (	+	2.67	±	8.83	 vs.	 	−	3.23	±	7.76	mg/dl,	 p	=	0.008)	
compared with the placebo. Finally, cholecalciferol supplemen-
tation	 led	 to	 a	 significant	 rise	 in	 plasma	 TAC	 concentrations	
(	+	79.00	±	136.69	 vs.	 	−	66.91	±	176.02	mmol/l,	 p	=	0.001)	 com-
pared	with	 the	 placebo.	 There	were	 no	 significant	 differences	
between the cholecalciferol and placebo groups in terms of 
changes	in	FPG,	other	lipid	profiles,	biomarkers	of	inflammation	
and oxidative stress and blood pressures.
Baseline	levels	of	SBP	were	significantly	different	between	the	2	
groups. Therefore, we controlled the analyses for the baseline 
levels.	However,	 after	 this	 adjustment	no	 significant	 changes	 in	
our	 findings	 occurred,	 except	 for	 plasma	 NO	 levels	 (p	<	0.001)	
Table S1. Further adjustments for maternal age and baseline BMI 
did	not	affect	our	findings,	except	for	serum	HDL-cholesterol	lev-
els	(p	=	0.06)	and	systolic	blood	pressure	(SBP)	(p	=	0.04).
We	did	find	no	significant	change	in	cesarean	section	rate,	gesta-
tional age, preterm delivery, newborn’s birth size, Apgar scores, 
pre-eclampsia	rate	and	LBW	comparing	the	2	groups	(	●▶	 Table 2).
Discussion
▼
The current study demonstrated that high-dose vitamin D 
administration among women at risk for pre-eclampsia had 
beneficial	 effects	 on	 insulin	 metabolism	 parameters,	 serum	
HDL-cholesterol, and plasma TAC concentrations, but did not 
affect	FPG,	other	lipid	profiles,	 inflammatory	factors	and	other	
biomarkers of oxidative stress. To the best of our knowledge, the 
current	 study	 is	 the	 first	 evaluating	 the	 effects	 of	 high-dose	
cholecalciferol administration on metabolic status and preg-
nancy outcomes in pregnant women at risk for pre-eclampsia 
according to abnormal uterine artery Doppler waveform. It must 
be kept in mind that participants in the current study were preg-
nant	women	who	have	vitamin	D	deficiency	by	definition	and	in	
addition they have a very low vitamin D intake. Therefore, vita-
min D supplementation with appropriate dosage is suggested in 
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vitamin	 D	 deficient	 pregnant	 women.	 In	 addition,	 we	 used	 a	
dose	of	approximately	4	000	IU	vitamin	D	supplements	daily	in	
the current study, which is higher than the current recom-
mended	 dietary	 allowance	 (600	IU/day)	 or	 standard	 prenatal	
supplement	dose	(400	IU/day).	However,	this	dose	is	the	tolera-
ble upper intake levels advised by the Institute of Medicine 
(IOM)	[25]	and	this	is	no	problem	in	this	short	study	of	12	weeks.
Pre-eclampsia is associated with fetal and maternal complica-
tions [26]. Our study demonstrated that high-dose cholecalcif-
erol intake for 12 weeks in women at risk for pre-eclampsia 
resulted	 in	 significant	 differences	 in	 serum	 insulin	 concentra-
tions, HOMA-IR score, HOMA-B, and QUICKI score compared 
with	the	placebo,	but	did	not	affect	FPG.	Moreover,	only	limited	
data	are	available	assessing	the	beneficial	effects	of	cholecalcif-
erol administration on metabolic status in pregnant women at 
risk for pre-eclampsia. Among women without risk for pre-
eclampsia	as	well	as	 in	animal	models,	 the	favorable	effects	of	
taking vitamin D on glucose homeostasis parameters have been 
shown.	 In	 agreement	 with	 our	 study,	 Soheilykhah	 et	 al.	 [27]	
showed that 50 000 IU cholecalciferol intake every 2 weeks from 
week 12 of pregnancy until delivery led to improved insulin 
resistance in healthy pregnant women. In our previous study 
among women with GDM, we also observed improved markers 
of insulin metabolism following the consumption of 100 000 IU 
cholecalciferol supplements for 6 weeks [12]. However, some 
researchers	did	not	see	such	beneficial	effects	of	cholecalciferol	
administration on insulin function. For instance, taking vitamin 
D	supplements	had	no	beneficial	effects	on	insulin	resistance	in	
patients	with	type	2	diabetes	mellitus	(T2DM)	after	24	weeks	of	
intervention	[28]	and	after	6	months	of	therapy	[29].	Further-
more, supplementation with 1 000 IU vitamin D daily did not 
affect	 insulin	 resistance	 among	 healthy	 overweight	 or	 obese	
women	for	12	weeks	[30].	Impaired	insulin	metabolism	is	asso-
ciated	with	arterial	stiffness	and	coronary	heart	disease	(CHD)	
independent of glucose tolerance status and increased hyper-
tension	 [31].	 Increased	 cholecalciferol	 concentration	 suppres-
sion	 of	 inflammatory	 factors	 and	 increased	 expression	 of	 the	
insulin	receptor	and/or	proteins	of	the	insulin-signaling	cascade	
may	result	in	improved	insulin	function	[32].
Findings from the current study showed that pregnant women 
who	received	high-dose	of	vitamin	D	supplements	had	a	signifi-
cant rise in serum HDL-cholesterol concentrations compared 
with	the	placebo,	but	had	no	significant	improvement	in	other	
Table 2	 The	effect	of	vitamin	D	supplementation	on	pregnancy	outcomes.	*	
Placebo group 
(n = 30)
Vitamin D 
group (n = 30)
p ** 
Cesarean section ( %) 10 (33.3) 9 (30.0) 0.78†
Gestational age (weeks) 39.1 ± 1.3 39.4 ± 1.3 0.31
Preterm delivery ( %) 1 (3.3) 0 (0) 0.31†
Newborns’ weight (g) 3 141.0 ± 495.9 3 313.6 ± 341.1 0.12
Newborns’ length (cm) 50.4 ± 2.1 50.9 ± 1.5 0.29
Newborns’ head circumference (cm) 34.7 ± 1.5 34.4 ± 0.8 0.26
1-min Apgar score 8.9 ± 0.2 8.9 ± 0.3 0.30
5-min Apgar score 9.9 ± 0.2 9.9 ± 0.3 0.30
Pre-eclampsia rate ( %) 3 (10.0) 1 (3.3) 0.30†
LBW ( %) 2 (6.7) 0 (0) 0.15†
	*	Values	are	means	±	SDs
	**	Obtained	from	independent	t-test
† Obtained from Pearson Chi-square test
For abbreviation, see text
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lipid	profiles.	In	line	with	our	study,	a	2-month	supplementation	
of 100 000 IU vitamin D increased HDL-cholesterol concentra-
tions	in	school	children	[33].	In	addition,	vitamin	D	plus	calcium	
administration	(400	IU	of	vitamin	D3	daily	+	1	000	mg	of	elemen-
tal	calcium)	resulted	in	a	significant	increase	in	HDL-cholesterol	
concentrations	among	postmenopausal	women	[34].	However,	
some	researchers	did	not	observe	any	significant	effect	of	taking	
cholecalciferol	 supplements	 on	 lipid	 concentrations	 [35,	36].	
Increased HDL-cholesterol concentrations in the presents study 
may result from form the stimulation of apolipoprotein A1 by 
cholecalciferol	 [37].	 The	absence	of	 significant	effect	of	 taking	
cholecalciferol	supplements	on	other	lipid	profiles	in	our	study	
might be explained by distinct trial designs, various dosages of 
cholecalciferol supplementation, and subjects of the study.
We have revealed here that the administration of cholecalciferol 
supplements	did	not	affect	serum	hs-CRP	and	plasma	NO	levels	
in pregnant women at risk for pre-eclampsia. In accordance with 
the	present	study,	no	significant	change	in	CRP	concentrations	
was	observed	after	the	vitamin	D	intake	(1	000,	2	000,	or	4	000	IU/
day	 of	 vitamin	 D3	 orally)	 for	 3	 months	 [38].	 Furthermore,	
1	000	mg	calcium	per	day	and	50	000	IU	vitamin	D3	pearl	2	times	
during	the	study	(at	study	baseline	and	day	21	of	intervention)	
co-supplementation	 did	 not	 affect	 hs-CRP	 and	NO	 concentra-
tions among GDM patients after 6 weeks [10]. In disagreement, 
a	9-week	administration	of	400	IU	vitamin	D	supplements	was	
associated	with	a	significant	decrease	in	serum	hs-CRP	concen-
trations	among	healthy	pregnant	women	[39].	In	addition,	in	an	
in	vitro	study,	concomitant	incubation	with	1,25(OH)₂D	reduced	
interleukin-6	(IL-6)	by	32	%,	and	of	IL-8	levels	by	34	%	[40].
We have demonstrated that high-dose cholecalciferol intake 
resulted	 in	 a	 significant	 rise	 in	 plasma	 TAC	 concentrations	 in	
pregnant women at risk for pre-eclampsia compared with the 
placebo,	but	did	not	influence	on	other	biomarkers	of	oxidative	
stress. In consistent with this trial, cholecalciferol supplementa-
tion	significantly	decreased	liver	oxidative	stress	index	(OSI)	and	
improved	 serum	 TAC	 concentrations	 in	 diabetic	 rats	 [41].	 In	
addition,	our	findings	are	in	accordance	with	those	reported	by	
other researchers, showing decreased oxidative DNA damage in 
the normal human colorectal mucosa following cholecalciferol 
and	calcium	supplementation	[42].	However,	supplementation	
of	50	000	IU	vitamin	D3	every	14	days	for	4	months	among	adult	
patients	with	nonalcoholic	 fatty	 liver	disease	 (NAFLD)	did	not	
affect	TAC	concentrations,	but	led	to	amelioration	in	MDA	con-
centrations [11]. Increased oxidative stress and free radicals is 
regarded as a main factor in the pathogenesis and progression of 
diabetes	mellitus	and	cardiovascular	complications	[43].	Accu-
rate	 explanation	 to	 the	 antioxidative	 effects	 of	 cholecalciferol	
supplements cannot be provided, but these may include stabili-
zation	of	the	plasma	membrane	against	lipid	peroxidation	[44]	
or upregulation of antioxidant systems including glutathione 
peroxidase	 (GPX)	 and	 superoxide	 dismutase	 (SOD),	 via	 its	
nuclear	receptors	[45].
The	 current	 study	 revealed	 no	 significant	 effect	 of	 high-dose	
cholecalciferol supplementation on pregnancy outcome. Our 
findings	are	accordance	with	previous	studies	showing	supple-
mentation with cholecalciferol did show no association between 
maternal vitamin D status in HIV-infected pregnant women and 
adverse	pregnancy	outcomes	 [46].	 In	 addition,	 taking	25	mg/d	
ergocalciferol	in	pregnant	women	did	not	influence	mean	birth	
weight	in	other	studies	[47,	48].	Others	did	not	find	a	significant	
effect	of	vitamin	D	effect	on	pregnancy	outcomes	[49,	50].	Dis-
crepancies between our study and others might be explained by 
the	different	doses	of	cholecalciferol	used	as	well	as	participants	
of the study.
While interpreting some limitations need to be taken into 
account. Due to limited funding, we in the current study did not 
assess	the	effect	of	cholecalciferol	administration	on	other	bio-
markers	of	systemic	inflammation	including	interleukin	1(IL-1),	
IL-6,	 and	 tumor	 necrosis	 factor	 alpha	 (TNF-α)	 as	well	 as	 bio-
markers of oxidative stress such as catalase and SOD. Further-
more, the appropriate dosage of vitamin D supplementation in 
pregnant women with at risk for pre-eclampsia cannot be 
inferred from this study and additional data would be required.
In conclusion, the administration of cholecalciferol supplementa-
tion	 for	 12	 weeks	 had	 favorable	 effects	 on	 insulin	 metabolism	
parameters, serum HDL-cholesterol and plasma TAC concentra-
tions,	while	it	did	not	affect	FPG,	other	lipid	concentrations,	inflam-
mation, oxidative stress, blood pressures, and pregnancy outcomes.
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